Syphilis Vaccine Development: Requirements, Challenges, and Opportunities

Area of Science:

• Infectious Diseases
• Vaccinology
• Microbiology

Background:

• Syphilis, caused by Treponema pallidum subspecies pallidum, remains a significant global health concern, particularly in low- and middle-income countries.
• Reemergence in high-income nations, especially among men who have sex with men, highlights the need for novel control strategies beyond traditional public health measures.
• Current control relies on screening and treatment, which are insufficient to curb rising case numbers and achieve elimination goals.

Purpose of the Study:

• To provide a comprehensive overview of the syphilis vaccine development pipeline.
• To define preferred product characteristics for an effective syphilis vaccine.
• To propose a vaccinogen selection strategy based on Treponema pallidum's pathogenic mechanisms.

Main Methods:

• Review of current syphilis epidemiology and control challenges.
• Analysis of Treponema pallidum pathogenesis to inform vaccine design.
• Evaluation of potential vaccine candidates and necessary adjuvant properties.
• Consideration of the investment case for syphilis vaccine development.

Main Results:

• Syphilis elimination necessitates the integration of vaccine development with existing public health initiatives.
• Optimal vaccine candidates must target specific pathogenic mechanisms of T. pallidum.
• Adjuvants are crucial for eliciting protective immune responses against syphilis infection/disease.
• A strategic approach to vaccinogen selection is essential for vaccine efficacy.

Conclusions:

• A multifaceted approach, including vaccine development, is critical for syphilis control and elimination.
• Understanding T. pallidum's biology is key to designing effective vaccine candidates.
• Investment and strategic planning are vital to advance syphilis vaccine development and implementation.